Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/1998

01-02-1998 | ORIGINAL ARTICLE

Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation

Authors: Jinbiao Zhan, Patrick Stayton, Oliver W. Press

Published in: Cancer Immunology, Immunotherapy | Issue 1/1998

Login to get access
Metadata
Title
Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation
Authors
Jinbiao Zhan
Patrick Stayton
Oliver W. Press
Publication date
01-02-1998
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050460

Other articles of this Issue 1/1998

Cancer Immunology, Immunotherapy 1/1998 Go to the issue

ORIGINAL ARTICLE

Interleukin-2: hope in cases of cisplatin-resistant tumours

ORIGINAL ARTICLE

Generation of killer activity by interleukin-12 of mononuclear cells in malignant pleural effusions due to lung cancer

SHORT COMMUNICATION

Stable expression of a retrovirally transferred adhesion molecule in a human melanoma-specific cytotoxic T lymphocyte clone

ORIGINAL ARTICLE

Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model

ORIGINAL ARTICLE

Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants

ORIGINAL ARTICLE

Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits